Financial Performance - The company's operating revenue for Q1 2025 was CNY 76,193.42 million, an increase of 8.62% compared to CNY 70,147.60 million in the same period last year[3]. - The net profit attributable to shareholders decreased by 136.67% to -CNY 2,215.69 million from CNY 6,042.96 million year-on-year[3]. - Total operating revenue for Q1 2025 reached ¥761,934,162.14, an increase of 8.6% compared to ¥701,476,021.12 in Q1 2024[17]. - Net profit for Q1 2025 was a loss of ¥33,810,178.34, compared to a profit of ¥50,826,577.08 in Q1 2024[18]. - Operating profit for Q1 2025 was a loss of ¥30,078,404.23, down from a profit of ¥67,215,203.83 in Q1 2024[17]. - The company's total equity decreased to ¥4,668,922,499.79 in Q1 2025 from ¥4,699,031,695.31 in Q1 2024[15]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.07, compared to ¥0.29 in Q1 2024[18]. Cash Flow - The net cash flow from operating activities was CNY 144.95 million, a significant recovery from -CNY 8,046.50 million in the previous year[3]. - In Q1 2025, the cash inflow from operating activities was CNY 790,053,802.93, a significant increase of 49% compared to CNY 530,126,166.70 in Q1 2024[20]. - The net cash flow from operating activities turned positive at CNY 1,449,459.10, recovering from a loss of CNY 80,464,953.10 in the same quarter last year[20]. - The company’s cash flow statement for Q1 2025 indicates ongoing financial challenges, with significant losses reported[19]. - The ending cash and cash equivalents balance decreased to CNY 1,188,903,291.84 from CNY 1,207,722,867.11, reflecting a decline of 1.5% year-over-year[21]. - The company received CNY 72,588,969.38 in tax refunds, significantly higher than CNY 61,571.52 in Q1 2024, indicating improved cash flow management[20]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 847,401.00 million, a 1.41% increase from CNY 835,655.97 million at the end of the previous year[4]. - Total liabilities increased to ¥3,805,087,477.12 in Q1 2025, compared to ¥3,657,528,028.71 in Q1 2024[15]. - The company's total current assets amounted to approximately CNY 3.77 billion, an increase from CNY 3.73 billion as of December 31, 2024, reflecting a growth of about 1.5%[13]. - The equity attributable to shareholders decreased by 0.40% to CNY 456,971.83 million from CNY 458,817.42 million at the end of the previous year[4]. Research and Development - R&D investment totaled CNY 5,469.71 million, representing 7.18% of operating revenue, up from 6.71% in the previous year[4]. - R&D expenses increased by CNY 7.65 million for key technology breakthroughs[6]. - Research and development expenses for Q1 2025 were ¥54,697,141.01, an increase from ¥47,047,391.14 in Q1 2024[17]. Shareholder Information - The top shareholder, Guotou (Shanghai) Venture Capital Management Co., holds 37,645,989 shares, representing 12.29% of total shares[10]. - The second-largest shareholder, Liaoning Kefa Industrial Co., Ltd., holds 14,800,000 shares, accounting for 4.83% of total shares[10]. - There are no significant changes in the shareholder structure or any related party transactions reported during the period[11]. Operating Costs - Total operating costs for Q1 2025 were ¥773,272,351.97, up 16.2% from ¥665,495,824.85 in Q1 2024[17]. - Cash outflow for purchasing goods and services was CNY 420,636,277.60, up from CNY 349,020,052.07, reflecting a 20.5% increase year-over-year[20]. - Total cash outflow for operating activities was CNY 788,604,343.83, up from CNY 610,591,119.80, representing a 29% increase year-over-year[20]. Investment Activities - The cash inflow from investment activities was CNY 10,252,868.67, a decrease of 98.9% from CNY 912,475,920.00 in Q1 2024[21]. - The net cash flow from investment activities was negative at CNY -207,057,779.30, compared to CNY -347,148,758.24 in the previous year, indicating a reduced loss[21]. - Cash inflow from financing activities was CNY 242,887,552.60, an increase of 13.4% from CNY 214,134,954.82 in Q1 2024[21]. - The net cash flow from financing activities improved to CNY 154,488,962.80, compared to CNY 94,237,960.43 in the same quarter last year, marking a 64% increase[21].

Financial Performance - Operating revenue for Q1 2025 was CNY 38,816,972.60, a decrease of 11.73% from CNY 43,975,693.12 in the same period last year[10] - Net profit attributable to shareholders increased by 5.56% to CNY 5,856,864.22, up from CNY 5,548,143.05 year-on-year[10] - Total operating revenue for Q1 2025 was ¥38,816,972.60, a decrease of 11.8% compared to ¥43,975,693.12 in Q1 2024[32] - Net profit for Q1 2025 reached ¥5,856,898.44, representing an increase of 5.6% from ¥5,548,022.99 in Q1 2024[33] - Operating profit for Q1 2025 was ¥6,491,737.86, slightly up from ¥6,219,939.59 in Q1 2024, indicating a growth of 4.4%[33] - Total comprehensive income for Q1 2025 was ¥5,856,898.44, compared to ¥5,548,022.99 in Q1 2024, showing an increase of 5.6%[34] Cash Flow - The net cash flow from operating activities was negative at CNY -2,572,029.61, a decline of 143.49% compared to CNY 5,914,487.64 in the previous year[10] - Cash inflow from operating activities for Q1 2025 was CNY 64,687,484.80, a decrease of 29.5% compared to CNY 91,734,852.55 in Q1 2024[37] - Net cash outflow from operating activities for Q1 2025 was CNY -2,572,029.61, contrasting with a net inflow of CNY 5,914,487.64 in Q1 2024[38] - Cash inflow from investment activities for Q1 2025 was CNY 76,245,837.52, an increase of 22.3% from CNY 62,332,039.79 in Q1 2024[39] - Net cash flow from investment activities for Q1 2025 was CNY 19,867,375.69, compared to a net outflow of CNY -1,842,149.36 in Q1 2024[38] - Cash inflow from financing activities for Q1 2025 was CNY 24,388,710.90, up from CNY 19,183,354.77 in Q1 2024[39] - Net cash flow from financing activities for Q1 2025 was CNY 7,651,872.44, compared to a net outflow of CNY -4,938,239.11 in Q1 2024[40] - The net increase in cash and cash equivalents for Q1 2025 was CNY 24,947,218.52, while there was a decrease of CNY -865,900.83 in Q1 2024[38] - The ending balance of cash and cash equivalents for Q1 2025 was CNY 70,541,460.76, compared to CNY 40,185,977.67 in Q1 2024[38] Assets and Liabilities - Total assets increased by 4.35% to CNY 374,570,234.35 as of March 31, 2025, compared to CNY 358,950,442.43 at the end of 2024[10] - The company’s debt-to-asset ratio (consolidated) rose to 32.97% from 31.68% year-on-year[10] - Current liabilities rose to CNY 123.32 billion, up from CNY 113.55 billion, indicating an increase of about 8.5%[27] - Non-current assets totaled CNY 63.32 billion, compared to CNY 60.57 billion, reflecting a growth of approximately 4.5%[27] - Total liabilities amounted to CNY 119.16 billion, up from CNY 113.45 billion, indicating an increase of about 5.8%[31] - Owner's equity increased to CNY 251.08 billion from CNY 245.22 billion, marking a rise of about 2.4%[28] Shareholder Information - The total number of ordinary shareholders was 5,630 as of the report date[17] - The total number of shares held by the top ten shareholders is 68,394,690, representing 67.6170% of the total shares[19] - Huang Caixia holds 46,735,283 shares, accounting for 46.2039% of the total shares[18] Inventory and Expenses - Sales expenses rose by 33.10% to CNY 2,619,615.03, reflecting increased costs associated with business expansion[12] - The company's inventory increased to 46,631,125.69 yuan from 37,233,500.98 yuan[26] - Research and development expenses for Q1 2025 were ¥1,562,272.82, a slight increase of 3.4% compared to ¥1,511,621.49 in Q1 2024[32] - Financial expenses in Q1 2025 were ¥397,369.56, up 88.9% from ¥210,266.15 in Q1 2024, primarily due to increased interest expenses[32] Other Financial Metrics - The retained earnings rose to CNY 98.43 billion from CNY 92.29 billion, reflecting an increase of approximately 6.5%[31] - The company reported a total of CNY 10 billion in deferred tax assets, up from CNY 9.54 billion, indicating a growth of about 4.8%[30] - The company reported cash and cash equivalents of 81,883,648.83 yuan as of March 31, 2025, an increase from 60,317,558.54 yuan on December 31, 2024[26] - The total current assets amount to 311,248,578.83 yuan, up from 298,378,779.68 yuan in the previous period[26] - Fixed assets rose to 17,726,696.38 yuan compared to 16,473,096.08 yuan previously[26] - The company has no pledged or judicially frozen shares among the top shareholders[20] - There were no significant legal disputes or external guarantees reported during the period[22] - The company has not engaged in any major asset acquisitions or disposals during the reporting period[22] - The company has fulfilled its previously disclosed commitments in a timely manner[22]

Regulatory and Industry Standards - The company participated in the formulation of the national mandatory standard for energy consumption limits in the refining industry, effective from May 1, 2025[4]. - The chemical industry is undergoing a transformation towards high-end, green, and digital development, driven by dual carbon goals and sustainable growth policies[49]. - Recent regulations emphasize the importance of green materials and sustainable practices in the chemical industry, with specific targets set for carbon neutrality and energy efficiency[181]. - The government is promoting the green transformation of traditional manufacturing sectors, including chemicals, to enhance sustainability[184]. Innovation and Research & Development - The company applied for 22 national patents during the reporting period, including 6 invention patents and 16 utility model patents, with 16 patents granted[12]. - The company is actively enhancing its R&D capabilities by attracting high-end scientific personnel to support long-term growth[48]. - The company achieved a research and development expenditure of ¥24,563,871.72, representing 4.55% of operating revenue, compared to ¥21,890,948.27 and 4.58% in the previous period[95]. - The total number of R&D personnel increased from 60 to 67, with the proportion of R&D staff to total employees rising from 17.44% to 18.26%[96]. - The company holds a total of 172 patents, up from 160 in the previous period, including 73 invention patents[97]. Financial Performance - The company’s operating revenue for 2024 was CNY 539,592,663.64, representing a 12.89% increase compared to CNY 477,980,447.37 in 2023[31]. - The net profit attributable to shareholders of the listed company was a loss of CNY 3,452,716.65, a decrease of 115.30% from a profit of CNY 22,569,060.74 in 2023[31]. - The total assets increased by 4.07% to CNY 992,769,159.24 at the end of 2024, compared to CNY 953,964,753.93 at the end of 2023[32]. - The total liabilities rose by 22.59% to CNY 348,225,654.41, up from CNY 284,055,763.20 in 2023[32]. - The gross profit margin for 2024 was 17.53%, slightly up from 17.05% in 2023[31]. Market Position and Strategy - The company is engaged in the research, production, and sales of green technology industrialized products, including tetrahydrofuran and toluene oxidation series products[25]. - The company’s annual production capacity for tetrahydrofuran is projected to reach 30,000 tons, which will increase its market share and position as the largest domestic producer using the LBDO purification method[50]. - The company is positioned within a tight industrial chain cluster, enhancing its competitive edge in the BDO industry[108]. - The company aims to deepen its main business in toluene oxidation series products and tetrahydrofuran, focusing on energy-saving expansion and cost reduction projects to enhance production capacity and economic efficiency[113]. Environmental and Compliance Efforts - The company is committed to sustainable development through the application of synthetic biology and green chemistry principles[111]. - The company maintains a strong focus on environmental protection and compliance with relevant laws and regulations[104]. - The company has implemented measures to address environmental protection risks associated with its production processes, ensuring compliance with pollution control standards[118]. Shareholder and Corporate Governance - The company has initiated a share repurchase plan with a total budget of 10,000,000 to 20,000,000 CNY, aiming to buy back between 781,250 and 1,562,500 shares, which is 0.94% to 1.88% of its total share capital[131]. - The company has successfully completed its share repurchase plan, acquiring 1,280,000 shares at an average price of 12.28 CNY per share, totaling 11,779,583.28 CNY[132]. - The company has established a comprehensive internal control system to enhance risk prevention capabilities and ensure compliance with relevant laws and regulations[115]. - The company has a total of 127,877,500.00 CNY in external guarantees, which accounts for a significant portion of its financial commitments[129]. Human Resources and Employee Development - The total number of employees increased from 344 to 367, with a net addition of 23 employees during the reporting period[171]. - A comprehensive training program has been implemented to improve employee skills and capabilities, including leadership training for mid-level managers and technical training for R&D personnel[174]. - The company has established a human resource planning system aligned with its strategic goals, focusing on competitive compensation and performance incentives to enhance employee motivation[173]. Legal and Risk Management - The company is currently involved in a lawsuit as a defendant, with a cumulative amount of 32,000,000 CNY, representing 4.96% of its net assets[124]. - The company has frozen bank account funds amounting to 32 million yuan due to legal disputes, but other funds in the account remain available for normal operations[137]. - The company has not identified any new major risk factors during the reporting period[120]. - The company has not experienced any significant changes in major risk factors during the reporting period[1].

Financial Performance - Operating revenue for the first quarter of 2025 was CNY 115,716,247.40, down 4.09% year-on-year[8] - Net profit attributable to shareholders for the first quarter of 2025 was a loss of CNY 746,900.07, representing a decline of 130.31% compared to the same period last year[8] - The weighted average return on equity based on net profit attributable to shareholders was -0.14% for the first quarter of 2025, down from 0.44% in the previous year[8] - Net profit for Q1 2025 was a loss of CNY 1,254,527.11, compared to a net profit of CNY 6,227,468.62 in Q1 2024, indicating a significant decline[35] - The total comprehensive income attributable to the parent company was -751,577.04 yuan, compared to 2,464,822.50 yuan in the previous year[36] - Basic and diluted earnings per share were both -0.01 yuan, down from 0.0296 yuan in the same period last year[36] Cash Flow - The net cash flow from operating activities decreased by 69.37% to CNY 3,921,241.83 compared to the previous year[8] - Net cash flow from operating activities amounted to $21,554,054.56, an increase from $16,301,051.07 in the previous period, representing a growth of approximately 32.8%[41] - Cash flow from financing activities generated a net inflow of 19,639,164.86 yuan, compared to a net outflow of -872,597.52 yuan in the previous year[39] - Cash inflow from investment activities was 145,335,639.40 yuan, compared to 10,178,018.58 yuan in the same period last year[39] - The ending balance of cash and cash equivalents was 89,970,075.71 yuan, up from 74,483,947.96 yuan in Q1 2024[39] - The net increase in cash and cash equivalents was -$1,169,509.08, compared to -$7,948,532.21 in the previous period, showing an improvement in cash management[41] Assets and Liabilities - Total assets as of March 31, 2025, were CNY 981,346,351.43, a decrease of 1.15% compared to the end of the previous year[8] - The company's asset-liability ratio (consolidated) was 34.33%, a slight decrease from 35.08% at the end of the previous year[8] - Total liabilities decreased from CNY 348,225,654.41 to CNY 336,871,696.19, a reduction of approximately 3.9%[30] - Total current assets decreased from CNY 436,712,056.22 on December 31, 2024, to CNY 419,696,735.71 on March 31, 2025, a decline of approximately 3.7%[28] - Total non-current assets increased from CNY 556,057,103.02 to CNY 561,649,615.72, a growth of about 1.7%[29] Shareholder Information - The company has a total of 55,243,857 shares held by the top ten shareholders, representing 66.39% of the total shares[17] - The largest shareholder, Gao Wengao, holds 27.67% of the shares, with a total of 23,022,000 shares[16] Research and Development - Research and development expenses increased by 66.65% to CNY 7,696,788.65 due to increased investment in R&D[10] - Research and development expenses rose to CNY 7,696,788.65 in Q1 2025, up from CNY 4,618,555.66 in Q1 2024, reflecting an increase of approximately 66.8%[34] Financial Commitments and Guarantees - The company provided a guarantee for a bank credit limit of RMB 27,877,500 for its subsidiary, Hubei Kelin Bolun New Materials Co., Ltd.[21] - The company has pledged 65% of its equity in Ningxia Meibang Huanyu Chemical Co., Ltd. as collateral for a loan of RMB 100 million[21] - The company has a total of RMB 180,596,193.23 in assets under restriction, accounting for 18.40% of total assets[25] - The company has a frozen bank account with a total of RMB 32,000,000, which represents 3.26% of total assets[25] - The company has provided a guarantee for a credit limit of RMB 65 million for its subsidiary, with a guarantee amount of RMB 27,877,500[22] - The company has no significant risks or impacts from the pledged assets on its operations[24] Other Financial Metrics - Total operating costs increased to CNY 116,649,899.41 in Q1 2025 from CNY 112,933,484.89 in Q1 2024, marking an increase of about 3.0%[34] - The company reported a significant increase in financial expenses, with interest expenses rising to CNY 501,687.79 in Q1 2025 from CNY 647,062.37 in Q1 2024[34] - The company experienced a credit impairment loss of CNY -624,416.20 in Q1 2025, compared to CNY -1,128,501.04 in Q1 2024, indicating an improvement[35] - Other comprehensive income after tax for Q1 2025 was CNY -4,676.97, contrasting with CNY 738.03 in Q1 2024, showing a negative shift[35]

Industrial Development and R&D - The company is completing the industrial plant project in Hangzhou, expected to be operational in the second half of 2025, focusing on the production of precious metal catalytic materials and enhancing operational capabilities [7]. - The new industrial project will include three centers: a production center for new energy materials, a high-end materials R&D center, and an operations center to integrate supply chain management [7]. - The company is expanding its R&D capabilities and aims to enhance its core competitiveness and innovation levels continuously [9][10]. - The company has developed new products, including platinum-based catalysts for hydrogen fuel cells, enhancing its product offerings in the market [46]. - The company is focusing on the development of new products and technologies to enhance product performance and reduce costs, particularly in the precious metal catalyst sector [112]. - The company is actively developing new catalytic materials aimed at meeting stricter emission standards, which is expected to enhance its market competitiveness [98]. - The company is focusing on the development of palladium/alumina catalysts for coal and natural gas chemical applications, aiming to expand its market presence in these sectors [52]. - The company is committed to the domestic production of precious metal catalysts, with a focus on increasing market share and developing local capabilities [111]. - The company is focusing on expanding its market presence through new product development and technological advancements in catalytic materials [98]. - The company is collaborating with South Central University for the production and research of catalysts, aiming to optimize production technology and develop new products [102]. Financial Performance - The company's total revenue for 2024 was ¥1,061,608,140.89, representing a decrease of 22.08% compared to ¥1,362,415,750.08 in 2023 [31]. - The net profit attributable to shareholders for 2024 was ¥20,325,941.04, an increase of 75.04% from ¥11,612,490.86 in 2023 [31]. - The gross profit margin improved to 3.32% in 2024 from 2.23% in 2023 [31]. - Total assets decreased by 17.98% to ¥784,478,777.76 in 2024 from ¥956,413,439.78 in 2023 [32]. - Total liabilities were reduced by 52.62% to ¥148,669,835.46 in 2024 from ¥313,764,391.39 in 2023 [32]. - The company's current ratio increased to 3.49 in 2024 from 2.25 in 2023, indicating improved liquidity [32]. - The weighted average return on equity (ROE) based on net profit was 3.25% in 2024, up from 1.90% in 2023 [31]. - The basic earnings per share for 2024 was ¥0.12, a 71.43% increase from ¥0.07 in 2023 [31]. - The company reported a net cash flow from operating activities of ¥23,628,705.03, a decrease of 28.61% from ¥33,099,444.70 in 2023 [32]. - The company reported non-recurring gains totaling 7,428,269.42 in 2024, up 68.1% from 4,418,036.01 in 2023 [38]. Market Position and Strategy - The company has maintained its business model focused on the research, development, manufacturing, and recycling of precious metal catalytic materials, primarily serving the automotive, petrochemical, and pharmaceutical industries [46]. - The company aims to reduce reliance on foreign materials by targeting the domestic market for key materials, achieving performance levels that meet international standards [47]. - The company is focusing on talent acquisition to improve management and technical capabilities, ensuring alignment with future development needs [115]. - The company is actively optimizing its customer structure and strengthening long-term partnerships with core clients, leading to an increase in product sales and processing volume [51]. - The company is committed to leveraging capital markets to enhance its overall strength and capture industry opportunities for sustainable development [54]. Regulatory and Compliance Issues - The company received a warning letter from the China Securities Regulatory Commission for inaccurate disclosure of performance forecasts and financial data [146]. - The company was subject to disciplinary action from the Beijing Stock Exchange for disclosure violations, resulting in a public reprimand [147]. - The company’s management team, including the chairman and general manager, received individual warnings related to the disclosure issues [148]. - The company has confirmed the existence of external guarantees and significant related party transactions during the reporting period [124]. Environmental and Sustainability Initiatives - The company aims to significantly reduce pollutant emission intensity by 10% by 2025 as part of its industrial green development plan [200]. - By 2025, the company targets an 18% reduction in carbon dioxide emissions per unit of GDP compared to 2020 levels [200]. - The company plans to improve air quality, with a goal of achieving a 10% reduction in PM2.5 concentration and an 87.5% ratio of good air quality days by 2025 [200]. - The company emphasizes the importance of environmental protection in its production processes, adhering to national standards and conducting strict environmental assessments for projects [108]. Shareholder and Governance Information - The total number of ordinary shares is 163,800,000, with 78.62% being unrestricted shares at the end of the period [152]. - The company’s major shareholders include Yao Hong with 22,855,369 shares (13.95%) and Zheng Gang with 7,850,000 shares (4.79%) as of the end of the reporting period [155]. - The company’s core employees, Zheng Genlu and Yang Juhua, have left the company, impacting the shareholding structure [153]. - The company has established a compensation plan for 2024, which was approved by the shareholders' meeting [184]. - The company has not implemented any stock incentive plans for the reporting period [186]. Internal Control and Risk Management - The company is implementing stringent internal controls related to revenue recognition to mitigate risks associated with management's potential manipulation of financial results [104]. - The company emphasizes the importance of internal control management to enhance risk prevention capabilities [116]. - The company has established a comprehensive technical management system and a stable R&D team, accumulating core technologies and products with independent intellectual property rights [120].

Financial Performance - The company's revenue for Q1 2025 was CNY 108,926,965.45, a decrease of 2.23% compared to CNY 111,411,602.18 in the same period last year[4]. - Net profit attributable to shareholders was CNY 20,489,309.09, down 10.51% from CNY 22,895,905.48 year-on-year[4]. - The net profit after deducting non-recurring gains and losses was CNY 19,067,636.31, reflecting a decrease of 12.33% compared to CNY 21,748,197.24 in the previous year[4]. - Total operating revenue for Q1 2025 was ¥108,926,965.45, a decrease of 2.2% compared to ¥111,411,602.18 in Q1 2024[18]. - Net profit for Q1 2025 was ¥20,489,309.09, down 10.5% from ¥22,895,905.48 in Q1 2024[19]. - Operating profit for Q1 2025 was ¥23,351,343.17, a decrease of 12.5% from ¥26,588,025.98 in Q1 2024[18]. - Total operating costs for Q1 2025 were ¥88,936,260.56, an increase of 3.5% from ¥85,556,447.58 in Q1 2024[18]. - Basic and diluted earnings per share for Q1 2025 remained at ¥0.05, unchanged from Q1 2024[19]. - Other comprehensive income after tax for Q1 2025 was -¥107.34, reflecting a decrease compared to the previous year[19]. Cash Flow and Investments - Operating cash flow for the period increased significantly by 127.92%, reaching CNY 65,588,203.74, compared to CNY 28,776,793.07 in the same period last year[4]. - Cash flow from operating activities for Q1 2025 was ¥65,588,203.74, significantly up from ¥28,776,793.07 in Q1 2024[23]. - Cash flow from investing activities for Q1 2025 was -¥142,392,271.43, an improvement from -¥409,037,270.16 in Q1 2024[24]. - Cash and cash equivalents decreased to RMB 148,955,862.02 from RMB 225,785,781.43, representing a decline of approximately 34.1%[13]. - Cash and cash equivalents at the end of Q1 2025 were ¥148,955,862.02, down from ¥229,422,987.49 at the end of Q1 2024[24]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,468,663,744.92, an increase of 1.06% from CNY 1,453,304,093.20 at the end of the previous year[5]. - As of March 31, 2025, the total assets of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. amounted to RMB 1,468,663,744.92, an increase from RMB 1,453,304,093.20 as of December 31, 2024, reflecting a growth of approximately 1.4%[13]. - The company's current assets totaled RMB 983,289,086.99, slightly up from RMB 976,317,889.19, indicating a growth of about 0.99%[13]. - The accounts receivable decreased significantly from RMB 103,524,626.45 to RMB 63,321,304.26, a reduction of about 38.9%[13]. - The total liabilities decreased from RMB 180,299,755.44 to RMB 175,170,098.07, a decline of approximately 2.4%[15]. - The company's equity attributable to shareholders increased from RMB 1,273,004,337.76 to RMB 1,293,493,646.85, reflecting a growth of about 1.6%[15]. - The inventory remained relatively stable, with a slight decrease from RMB 102,418,450.82 to RMB 102,397,398.38[14]. - The non-current assets totaled RMB 485,374,657.93, up from RMB 476,986,204.01, indicating an increase of approximately 1.6%[14]. Research and Development - R&D investment totaled CNY 12,449,732.66, a decrease of 19.44% from CNY 15,454,452.53 year-on-year, representing 11.43% of revenue, down from 13.87%[5]. - Research and development expenses for Q1 2025 were ¥12,449,732.66, a decrease of 19.5% compared to ¥15,454,452.53 in Q1 2024[18]. Shareholder Information - The company had a total of 8,389 preferred shareholders with restored voting rights at the end of the reporting period[8]. - The largest shareholder, Shanghai Lianhe Investment Co., Ltd., holds 51.40% of the shares, totaling 233,000,000 shares[10]. - The company has not reported any significant changes in major shareholders or their participation in financing activities during the reporting period[12]. Non-Recurring Gains and Losses - Non-recurring gains and losses for the period amounted to CNY 1,421,672.78, with government subsidies contributing CNY 506,833.79[6][7]. - The weighted average return on equity decreased to 1.60%, down 0.28 percentage points from 1.88% in the previous year[5].

Financial Performance - The company's operating revenue for 2024 reached ¥511,619,303.14, a year-on-year increase of 70.61% compared to ¥299,871,288.42 in 2023[23]. - Net profit attributable to shareholders was ¥127,700,550.17, reflecting a significant growth of 109.09% from ¥61,074,068.07 in the previous year[23][25]. - The net profit after deducting non-recurring gains and losses was ¥113,965,967.97, up 140.06% from ¥47,473,745.81 in 2023[23][25]. - Cash flow from operating activities surged to ¥130,230,119.87, a remarkable increase of 905.01% compared to ¥12,958,036.70 in the previous year[23][27]. - Basic earnings per share rose to ¥0.28, marking a 115.38% increase from ¥0.13 in 2023[24][27]. - The weighted average return on equity increased to 10.37%, up 5.23 percentage points from 5.14% in the previous year[24][27]. - The total cash dividend for the year amounts to 27.84 million CNY, which includes 11.23 million CNY distributed in the mid-year[6]. - The combined amount of cash dividends and share repurchases for the year is approximately 63.96 million CNY, representing 50.09% of the net profit attributable to shareholders[6]. Research and Development - Research and development expenses accounted for 16.60% of operating revenue, a decrease of 8.08 percentage points from 24.68% in 2023[24][27]. - The total R&D expenditure for the year was approximately ¥84.92 million, an increase of 14.75% compared to the previous year's ¥74.01 million, with R&D expenditure accounting for 16.60% of operating revenue, down from 24.68%[79]. - The company has 19 products under development, with 5 products approved for domestic and international markets during the reporting period[36]. - A total of 16 new domestic patents were applied for during the reporting period, including 10 invention patents[37]. - The company has established three core technology platforms, enhancing its R&D capability and creating high barriers to entry in the market[87]. - The company has maintained a strong focus on independent R&D since its establishment, ensuring a solid foundation for the continuous development of high-value products[68]. - The company has a strong R&D team, with over 40% of its researchers holding master's degrees or higher, ensuring robust technical capabilities[90]. Market Expansion and Sales - The company is actively expanding its international market presence, focusing on the U.S. and emerging markets along the "Belt and Road" initiative[35]. - The company achieved foreign sales revenue of 20,794.62 million yuan, accounting for 40.69% of its main business income, indicating its reliance on international markets[95]. - The company recorded equity income of CNY 46.82 million, which is a 122.30% increase compared to the previous year[35]. - The company’s international sales revenue surged by 120.64% year-on-year, mainly due to substantial sales growth of Mesalazine enteric-coated tablets and Bupropion sustained-release tablets in the U.S.[117]. - The company’s main products, including posaconazole enteric-coated tablets and mesalazine enteric-coated tablets, have significant market shares in the U.S. market and are included in the National Basic Medical Insurance Drug List[89]. Quality Management and Compliance - The company has established a comprehensive quality management system, conducting 1 internal audit and passing 12 external inspections during the reporting period, ensuring stable production operations[39]. - The company received a zero-defect rating from the FDA during a routine cGMP inspection in March 2024, affirming the effectiveness of its quality management system[40]. - The company has established long-term partnerships with major suppliers to ensure stable and reliable material supply, employing various procurement models to maintain quality and cost-effectiveness[45]. - The company has received multiple awards for its CRO/CMO services, including recognition as one of the "Top Ten Innovative Drug Service Institutions" by Securities Times[38]. Risks and Challenges - The company faces risks related to raw material price fluctuations, which could impact future performance if prices rise significantly[96]. - The company has a receivables balance of 10,352.46 million yuan, indicating potential risks associated with accounts receivable as business expands[99]. - The company’s inventory value stands at 10,241.85 million yuan, posing risks related to the timely realization of inventory as business grows[100]. - The company faced risks related to the national centralized procurement policy, which may affect the pricing and sales of its products, particularly posaconazole enteric-coated tablets[106]. - The company’s foreign sales are significantly impacted by international regulations and geopolitical factors, which pose potential risks to its export business[108]. Corporate Governance - The company has established a robust governance structure, holding 8 board meetings and reviewing 35 proposals during the reporting period[174]. - The board of directors consists of 8 members, all of whom are external directors, including 3 independent directors, complying with legal and regulatory requirements[175]. - The supervisory board held 5 meetings during the reporting period, reviewing 16 proposals, ensuring compliance with relevant laws and regulations[176]. - The company has maintained independence from its controlling shareholder, with no instances of fund occupation or guarantees provided to the controlling shareholder[178]. - The company issued 5 voluntary disclosure announcements throughout the year, including 3 product approval announcements and 1 project bidding announcement, enhancing market transparency[179]. Future Outlook - The company plans to deepen its focus on high-end generic drugs and expand into improved new drugs, enhancing its competitive edge[168]. - The company aims to increase R&D investment, particularly in complex injection formulations, to transition from a generic drug company to a hybrid innovative pharmaceutical enterprise[169]. - The company will enhance its CRO/CMO services, expanding its client base and deepening cooperation with existing clients[170]. - The company intends to expand its market presence both domestically and internationally, particularly in emerging markets and along the "Belt and Road" initiative[171].

Financial Performance - The company reported a net profit attributable to shareholders of the listed company for 2024 as negative, indicating no cash dividend distribution for the year[6]. - The board of directors has approved a proposal to not distribute profits or increase capital reserves due to the negative profit situation and current economic conditions[6]. - The company's operating revenue for 2024 was RMB 7,522,592,470, a decrease of 38.21% compared to RMB 12,174,195,086.96 in 2023[23]. - The net profit attributable to shareholders for 2024 was a loss of RMB 870,370,890.86, an improvement from a loss of RMB 1,503,629,794.50 in 2023[23]. - The cash flow from operating activities for 2024 was RMB 1,573,304,662.87, a significant increase compared to a negative cash flow of RMB -1,558,051,064.93 in 2023[23]. - The company's total assets at the end of 2024 were RMB 17,676,221,687.15, down 9.03% from RMB 19,431,769,993.78 at the end of 2023[24]. - The basic earnings per share for 2024 was -7.00 yuan, an improvement from -11.93 yuan in 2023[25]. - The company's operating profit was CNY -99,251.49 million, representing an increase in losses of CNY 72,801.13 million compared to the previous year[109]. - The net profit attributable to the parent company was CNY -87,037.09 million, a year-on-year increase in losses of CNY 63,325.89 million[109]. Revenue and Sales Growth - The company reported a significant increase in revenue, achieving a total of 1.5 billion yuan, representing a 25% year-over-year growth[13]. - User data indicates a growth in active users, reaching 3 million, which is a 15% increase compared to the previous quarter[14]. - The company provided a positive outlook for the next quarter, projecting a revenue increase of 20% based on current market trends[14]. - The cumulative shipment of lithium iron phosphate reached 228,200 tons, an increase of 39.07% year-on-year[38]. - The company produced 233,108.08 tons of lithium iron phosphate, a 50.51% increase year-on-year, while sales volume increased by 39.07% to 228,239.97 tons[117]. Research and Development - The company is investing 200 million yuan in research and development for sustainable energy solutions over the next two years[14]. - The research and development expenditure as a percentage of operating revenue was 3.42% in 2024, a slight decrease from 3.46% in 2023[25]. - The company has applied for 90 domestic invention patents and 136 international invention patents, obtaining 80 various intellectual property rights and 23 core technologies[44]. - The company has developed a new sodium-ion battery cathode composite material with a simple preparation process and good reproducibility, suitable for industrial production[72]. - The company is actively developing solid-state battery technology, which is expected to have a significant impact on the electric vehicle and energy storage markets due to its high energy density and safety features[61]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the fiscal year[14]. - A strategic acquisition of a local competitor was completed, which is anticipated to increase market penetration by 5%[14]. - The company is focusing on the development of lithium iron phosphate materials, which are increasingly favored in both the electric vehicle and energy storage sectors due to their cost-effectiveness and performance[54]. - The company is exploring potential mergers and acquisitions to enhance its market position and technological capabilities[180]. - The company plans to invest approximately RMB 5 billion in a research and technology center and industrialization base project in Qingshan District, Wuhan, focusing on lithium-ion, sodium-ion, solid-state batteries, and hydrogen storage materials[149]. Governance and Compliance - The company has not experienced any non-operating fund occupation by controlling shareholders or related parties[8]. - There are no special arrangements for corporate governance applicable to the company[8]. - The company has confirmed that all board members attended the board meeting, ensuring accountability for the report's accuracy[5]. - The company emphasizes strict compliance with laws and regulations regarding information disclosure, ensuring timely and accurate reporting of significant events to protect investors' rights[175]. - The company has established multiple communication channels for investor relations, enhancing transparency and maintaining good relationships with investors[175]. Operational Efficiency and Cost Management - The company implemented stronger sales management and cost control measures, contributing to a narrowing of losses in key financial metrics[26]. - The company has implemented cost reduction and efficiency enhancement measures, which have helped mitigate the impact of raw material price fluctuations on its financial performance[96]. - The company has introduced an intelligent warehousing management system to enhance inventory management and reduce risks[41]. - The company is focusing on lean production to improve efficiency and reduce costs, employing TQM to enhance product quality management[40]. - The company plans to expand its market presence and improve customer service quality through enhanced logistics and inventory management[117]. Future Outlook - Future guidance includes an expected EBITDA margin of 15% for the upcoming fiscal year, up from 12%[14]. - The company anticipates a gradual easing of the supply-demand relationship in the lithium-ion battery cathode materials industry, leading to improved capacity utilization rates[54]. - The company aims to achieve industry-leading levels in its R&D projects, focusing on enhancing product quality and performance[81]. - The company is committed to innovation and development in the lithium battery cathode materials sector, supported by favorable government policies and market demand[50]. - The company is focusing on enhancing the knowledge and skills of its R&D personnel through specialized training programs[180].

Revenue and Profitability - The company's revenue for Q1 2025 reached ¥2,278,166,335.81, representing a 97.30% increase compared to ¥1,154,685,836.57 in the same period last year[3] - The net profit attributable to shareholders was -¥155,847,073.58, a decline from -¥130,059,834.70 year-on-year[3] - The net loss for Q1 2025 was ¥161,740,719.96, worsening from a net loss of ¥142,557,872.36 in Q1 2024[18] - The gross profit margin for Q1 2025 was approximately -7.5%, down from a margin of -13.0% in Q1 2024[18] Cash Flow and Financial Position - The net cash flow from operating activities was -¥465,468,176.92, a significant decrease of 171.77% compared to ¥648,537,906.95 in the previous year[3] - Net cash flow from operating activities in Q1 2025 was negative at approximately -$465.47 million, compared to a positive cash flow of $648.54 million in Q1 2024[22] - The company's cash and cash equivalents increased to ¥3,650,084,028.43 from ¥2,918,703,772.52, reflecting a growth of approximately 25.1%[13] - The company's cash and cash equivalents at the end of Q1 2025 stood at approximately $818.87 million, down from $2.12 billion at the end of Q1 2024[23] Assets and Liabilities - Total assets increased by 6.42% to ¥18,810,595,808.23 from ¥17,676,221,687.15 at the end of the previous year[4] - The total liabilities increased to ¥13,386,282,012.35 in 2025 from ¥12,088,654,080.57 in 2024, marking an increase of approximately 10.7%[15] - The equity attributable to shareholders decreased to ¥5,460,148,557.22 in 2025 from ¥5,617,508,721.54 in 2024, a decline of approximately 2.8%[15] Research and Development - Research and development expenses totaled ¥65,143,066.00, accounting for 2.86% of revenue, down from 6.52% in the previous year[3] - Research and development expenses for Q1 2025 totaled ¥65,143,066.00, a decrease from ¥75,293,136.51 in Q1 2024, reflecting a reduction of about 13.5%[18] Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,859[8] - The largest shareholder, Liu Shiqi, holds 29,475,240 shares, representing 23.37% of the total shares[8] - The top 10 shareholders hold a combined total of 61.56% of the company's shares[9] Inventory and Receivables - The sales volume of lithium iron phosphate increased by 138% compared to the same period last year, driving revenue growth[6] - The company experienced an increase in accounts receivable, leading to a significant rise in bank acceptance bills issued for raw material purchases[6] - The company's inventory increased to ¥1,324,904,449.64 from ¥943,677,657.71, marking a rise of approximately 40.4%[13] - The accounts receivable balance was reported at ¥2,201,910,889.58, compared to ¥2,043,167,258.18 in the previous period[13] Government Support - The company received government subsidies amounting to ¥9,195,848.86, which positively impacted its financial results[5] Share Buyback Program - The company plans to implement a share buyback program with a minimum investment of ¥8.6067 million and a maximum of ¥17.2133 million[10] - The company has not yet executed the share buyback plan through the Shanghai Stock Exchange as of the reporting date[11] - The company will continue to disclose updates regarding the share buyback plan as progress is made[11] Operating Costs - Total operating costs for Q1 2025 were ¥2,449,246,162.15, compared to ¥1,382,200,250.38 in Q1 2024, indicating an increase of about 77.4%[18]

Financial Performance - The company's operating revenue for Q1 2025 reached ¥308,116,657.13, representing a significant increase of 444.91% compared to the same period last year[3]. - Total operating revenue for Q1 2025 reached ¥308.12 million, a significant increase from ¥56.54 million in Q1 2024, representing a growth of 444.4%[17]. - The net profit attributable to shareholders was -¥48,682,545.64, showing a decline from -¥35,071,604.36 in the previous year[3]. - Net loss for Q1 2025 was ¥54.53 million, worsening from a net loss of ¥37.12 million in Q1 2024, reflecting an increase in losses of 46.9%[18]. - The total comprehensive loss for Q1 2025 was ¥54.55 million, compared to a loss of ¥37.34 million in Q1 2024, an increase of 46.1%[18]. Cash Flow and Liquidity - The net cash flow from operating activities was -¥226,338,615.59, a decrease from -¥89,151,944.82 year-on-year[3]. - Cash flow from operating activities for Q1 2025 was negative at ¥226.34 million, compared to a negative cash flow of ¥89.15 million in Q1 2024[19]. - Cash and cash equivalents at the end of Q1 2025 stood at ¥175.74 million, down from ¥241.17 million at the end of Q1 2024, a decrease of 27.2%[20]. - The company's cash and cash equivalents decreased significantly from RMB 467,517,111.00 on December 31, 2024, to RMB 202,884,708.68, representing a decline of about 57%[13]. Expenses and Costs - Research and development expenses totaled ¥23,362,290.56, accounting for 7.58% of operating revenue, a decrease of 41.55 percentage points compared to 49.13% in the previous year[4]. - Research and development expenses for Q1 2025 were ¥23.36 million, slightly lower than ¥27.78 million in Q1 2024, a decrease of 15.9%[17]. - Total operating costs for Q1 2025 were ¥354.70 million, compared to ¥94.65 million in Q1 2024, indicating an increase of 274.5%[17]. - Sales expenses surged to ¥272.63 million in Q1 2025, compared to ¥21.57 million in Q1 2024, marking an increase of 1,264.5%[17]. - Management expenses increased due to a rapid expansion in the AI + security sector, impacting overall profitability[7]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,517,361,844.92, down 14.93% from the previous year-end[4]. - As of March 31, 2025, the company's total assets amounted to RMB 1,517,361,844.92, a decrease from RMB 1,783,686,923.54 as of December 31, 2024, reflecting a decline of approximately 15%[14]. - The company's total equity decreased from RMB 1,136,778,908.01 to RMB 1,089,764,095.00, reflecting a decline of about 4%[15]. - The company's total liabilities decreased from RMB 646,908,015.53 to RMB 427,597,749.92, a reduction of approximately 34%[15]. - The total current liabilities decreased from RMB 536,236,015.13 to RMB 315,085,753.40, a reduction of around 41%[15]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 5,104[10]. - The largest shareholder, Zhong Zhu, holds 23.69% of the shares, with 756,000 shares frozen[10]. Investment and Retained Earnings - The company's long-term investments remained stable at RMB 143,887,071.24 as of March 31, 2025[14]. - The company's retained earnings decreased from RMB 96,824,382.16 to RMB 55,369,486.31, a decline of about 43%[15]. - The company reported a significant increase in prepayments from RMB 37,889,716.49 to RMB 97,937,065.86, an increase of approximately 158%[13]. Return on Equity - The weighted average return on equity was -4.38%, a decrease of 1.43 percentage points from -2.95% in the previous year[4].